
Soleno Therapeutics SLNO
$ 47.59
-0.13%
Quarterly report 2025-Q3
added 11-04-2025
Soleno Therapeutics ROCE Ratio 2011-2025 | SLNO
Annual ROCE Ratio Soleno Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -76.57 | -26.27 | -235.77 | -177.19 | -56.68 | -69.85 | -33.28 | -25.96 | -352.82 | -242.78 | -72.61 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -25.96 | -352.82 | -124.53 |
Quarterly ROCE Ratio Soleno Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | -41.02 | -82.04 | -115.42 | -96.22 | -137.23 | -137.23 | -144.25 | -105.79 | -123.04 | -99.27 | -83.45 | -62.2 | -103.24 | -127.02 | -140.06 | -111.96 | -124.71 | -96.43 | -70.03 | -35.4 | -45.21 | -42.27 | -42.23 | -26.17 | -83.46 | -130.94 | -186.57 | -248.21 | -303.34 | -301.17 | -282.86 | -113.94 | -102.11 | -35.16 | -5.06 | -16.2 | -13.57 | -22.77 | -4.38 | 2.62 | 2.62 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.62 | -303.34 | -98.45 |
ROCE Ratio of other stocks in the Diagnostics research industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-89.9 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
58.25 | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
62.7 | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
-17.75 | $ 19.0 | -1.91 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-41.81 | $ 20.75 | -2.01 % | $ 223 M | ||
|
Co-Diagnostics
CODX
|
-47.68 | $ 0.23 | -3.91 % | $ 6.75 M | ||
|
Biocept
BIOC
|
-360.98 | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
-132.81 | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
1.9 | $ 39.22 | -0.44 % | $ 1.09 B | ||
|
Danaher Corporation
DHR
|
9.82 | $ 230.27 | -0.02 % | $ 168 B | ||
|
DarioHealth Corp.
DRIO
|
-66.97 | $ 10.22 | 1.79 % | $ 290 M | ||
|
BioNano Genomics
BNGO
|
-293.94 | $ 1.52 | -0.16 % | $ 1.93 M | ||
|
Exact Sciences Corporation
EXAS
|
-36.48 | $ 101.55 | -0.02 % | $ 18.8 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-2.26 | - | - | $ 562 M | ||
|
DexCom
DXCM
|
28.89 | $ 68.16 | 0.87 % | $ 26.3 B | ||
|
Enzo Biochem
ENZ
|
-22.04 | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
-6.52 | $ 26.59 | -0.47 % | $ 804 M | ||
|
Global Cord Blood Corporation
CO
|
12.48 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-18.87 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-347.69 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-15.41 | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-181.44 | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
9.75 | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-77.82 | $ 19.3 | -0.92 % | $ 1.04 B | ||
|
Celcuity
CELC
|
-97.97 | $ 100.62 | -1.59 % | $ 3.97 B | ||
|
Heska Corporation
HSKA
|
-4.81 | - | - | $ 1.31 B | ||
|
Anixa Biosciences
ANIX
|
-69.16 | $ 3.17 | -1.09 % | $ 101 K | ||
|
HTG Molecular Diagnostics
HTGM
|
-219.45 | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
36.29 | $ 226.44 | -0.21 % | $ 41.1 B | ||
|
Guardant Health
GH
|
317.65 | $ 102.14 | -0.82 % | $ 12.5 B | ||
|
Myriad Genetics
MYGN
|
-17.62 | $ 6.4 | -1.31 % | $ 580 M | ||
|
ENDRA Life Sciences
NDRA
|
-281.17 | $ 4.66 | -8.27 % | $ 2.5 M | ||
|
Neogen Corporation
NEOG
|
-51.22 | $ 7.27 | 1.89 % | $ 1.58 B | ||
|
Aspira Women's Health
AWH
|
-486.78 | - | -6.19 % | $ 10.5 M | ||
|
National Research Corporation
NRC
|
81.8 | $ 18.6 | -0.35 % | $ 456 M | ||
|
Koninklijke Philips N.V.
PHG
|
6.33 | $ 27.32 | 0.77 % | $ 20 B | ||
|
Personalis
PSNL
|
-33.64 | $ 8.14 | - | $ 482 M | ||
|
Quidel Corporation
QDEL
|
69.35 | $ 29.39 | 0.31 % | $ 1.24 B | ||
|
QIAGEN N.V.
QGEN
|
1.9 | $ 45.94 | 1.26 % | $ 10.2 B | ||
|
Illumina
ILMN
|
-35.1 | $ 134.51 | -0.33 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
6.57 | $ 202.78 | -0.43 % | $ 10.4 B | ||
|
RadNet
RDNT
|
11.59 | $ 72.71 | -0.6 % | $ 5.31 B | ||
|
Quest Diagnostics Incorporated
DGX
|
19.86 | $ 175.65 | -0.16 % | $ 19.5 B | ||
|
Biodesix
BDSX
|
-41.6 | $ 6.62 | -2.86 % | $ 858 M | ||
|
Motus GI Holdings
MOTS
|
-443.13 | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
13.5 | $ 253.7 | -0.07 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
4.69 | $ 181.2 | -0.9 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
50.7 | $ 687.59 | -0.13 % | $ 56.7 B | ||
|
Lantheus Holdings
LNTH
|
42.0 | $ 67.17 | 0.69 % | $ 4.65 B |